)
Edge6 Feb 2026
SharkNinja: Viral by Design
How SharkNinja built a repeatable growth engine, turning overlooked appliance categories into global brands through consumer insight and iteration.
VistaGen Therapeutics
VistaGen Therapeutics (VTGN) investor relations material
VistaGen Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary12 Feb, 2026
Executive summary
Completed randomized portion of PALISADE-3 Phase 3 trial in social anxiety disorder; topline results from PALISADE-4 expected in H1 2026, with operational refinements implemented.
Ongoing AI/ML analysis to optimize statistical models and understand placebo/active drug response across PALISADE studies.
Open-label extensions of PALISADE-3 and PALISADE-4 continue to assess safety and real-world use of fasedienol.
USAN adoption for PH80 (rafisolone) and IND submission planned for menopause-related vasomotor symptoms in H1 2026.
Appointment of Nick Tressler as Chief Financial Officer in December 2025.
Financial highlights
Cash, cash equivalents, and marketable securities totaled $61.8 million as of December 31, 2025.
Net loss was $18.9 million for the quarter and $53.4 million for the nine months ended December 31, 2025.
R&D expenses increased to $14.2 million for the quarter, mainly due to clinical development of fasedienol.
General and administrative expense rose to $5.6 million for the quarter, primarily due to higher consulting and professional fees.
Revenue was $0.3 million for the quarter and $0.8 million for the nine months, primarily from sublicense and collaboration agreements.
Outlook and guidance
On track to complete PALISADE-4 as guided, with topline results expected in H1 2026.
IND for rafisolone planned for submission in the first half of 2026 to support further Phase 2 development.
Substantial doubt exists about the ability to continue as a going concern beyond twelve months from the financial statement issuance date, absent additional financing.
Research and development and general and administrative expenses are expected to decrease due to cash preservation measures, but may increase if PALISADE-4 is successful and the program advances toward NDA submission.
Plans to seek additional capital through equity, debt, grants, or strategic partnerships.
Impact of AI/ML on PALISADE-4 regulatory strategy
Refisolone's competitive advantage in women's health
Cash preservation impact on Pherin pipeline advancement
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next VistaGen Therapeutics earnings date
Q4 202611 Jun, 2026
VistaGen Therapeutics
Next VistaGen Therapeutics earnings date
Q4 202611 Jun, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
VistaGen Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders. The company's pipeline includes drug candidates designed to address mental health conditions such as anxiety, depression, and social anxiety disorder. VistaGen’s lead programs aim to provide rapid-acting treatments that target specific CNS pathways, offering potential alternatives to traditional therapies. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage